Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-07-27, Stock:ABBV, The news for the past five days is as follows:
2018-07-20: NEWS1: Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?.NEWS2: Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?.NEWS3: Analysts’ Recommendations for Stryker and Its Peers in July.NEWS4: Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?.NEWS5: AbbVie Becomes Oversold (ABBV).NEWS6: AbbVie Becomes Oversold (ABBV).NEWS7: Analyzing AbbVie before Its Second-Quarter Earnings.NEWS8: Pharma Stock Roundup: JNJ & NVS&apos; Q2 Earnings, FDA Approvals.NEWS9: 3 Top Healthcare Stocks to Buy in July.NEWS10: 3 Top Healthcare Stocks to Buy in July.NEWS11: Today’s Research Reports on Stocks to Watch: eBay and AbbVie.NEWS12: 3 Top Healthcare Stocks to Buy in July.
2018-07-23: NEWS1: What’s Next for Pfizer Stock After Being Called Out by President Trump.NEWS2: With new attack on Alzheimer&apos;s, this young biotech is hiring, grabbing more space.NEWS3: Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?.NEWS4: Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?.NEWS5: Healthcare ETFs to Buy on Solid Q2 Earnings Expectations.NEWS6: Healthcare ETFs to Buy on Solid Q2 Earnings Expectations.NEWS7: Healthcare ETFs to Buy on Solid Q2 Earnings Expectations.NEWS8: Better Buy: Gilead Sciences, Inc. vs. Celgene.NEWS9: Better Buy: Gilead Sciences, Inc. vs. Celgene.NEWS10: AbbVie's Stock Is a Bargain After Falling 8% Last Week.NEWS11: AbbVie's Stock Is a Bargain After Falling 8% Last Week.NEWS12: Better Buy: Gilead Sciences, Inc. vs. Celgene.NEWS13: How Johnson & Johnson’s Earnings Trended in Q2 2018.NEWS14: AbbVie&apos;s Stock Is a Bargain After Falling 8% Last Week.
2018-07-24: NEWS1: Citron's Left reiterates belief AbbVie shares will fall sharply.NEWS2: AbbVie prices new endometriosis drug at $10,000 a year.NEWS3: Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?.NEWS4: Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?.NEWS5: Merck (MRK) Q2 Earnings Coming Up: What's in the Cards?.NEWS6: Merck (MRK) Q2 Earnings Coming Up: What's in the Cards?.NEWS7: Merck (MRK) Q2 Earnings Coming Up: What&apos;s in the Cards?.NEWS8: AbbVie Wins U.S. Approval for Endometriosis Pain Treatment.NEWS9: AbbVie Gets Approval for Endometriosis Pain Treatment.NEWS10: AbbVie Gets OK for Potential Blockbuster Endometriosis Treatment.NEWS11: Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?.NEWS12: What's in Store for Cardinal Health (CAH) in Q4 Earnings?.NEWS13: What's in Store for Cardinal Health (CAH) in Q4 Earnings?.NEWS14: AbbVie wins FDA approval for oral treatment for endometriosis pain.NEWS15: Eli Lilly Surpasses Estimates, Reports Growth in Q2 2018.NEWS16: AbbVie Receives U.S. FDA Approval of ORILISSA™ (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis.NEWS17: What to Expect When AbbVie Reports Q2 Earnings.NEWS18: What to Expect When AbbVie Reports Q2 Earnings.NEWS19: What&apos;s in Store for Cardinal Health (CAH) in Q4 Earnings?.NEWS20: J&J’s Oncology Franchise Saw 42.2% Growth in Q2 2018.NEWS21: What to Expect When AbbVie Reports Q2 Earnings.NEWS22: Validea John Neff Strategy Daily Upgrade Report - 7/24/2018.NEWS23: Validea John Neff Strategy Daily Upgrade Report - 7/24/2018.NEWS24: AbbVie Reports FDA Approval Of ORILISSA - Quick Facts.NEWS25: AbbVie Reports FDA Approval Of ORILISSA - Quick Facts.NEWS26: What’s Next for Pfizer Stock After Being Called Out by President Trump.NEWS27: What’s Next for Pfizer Stock After Being Called Out by President Trump.NEWS28: Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?.NEWS29: Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?.
2018-07-25: NEWS1: AbbVie Secures FDA Approval for Endometriosis Drug Elagolix.NEWS2: AbbVie Secures FDA Approval for Endometriosis Drug Elagolix.NEWS3: 3 'Strong Buy' Healthcare Stocks Poised to Surge.NEWS4: AbbVie Secures FDA Approval for Endometriosis Drug Elagolix.NEWS5: In pursuit of Alzheimer&apos;s, cancer, growing Alector lands $133 million.
2018-07-26: NEWS1: 5 Must-See Earnings Charts to End the Week.NEWS2: 5 Must-See Earnings Charts to End the Week.NEWS3: Keller Lenkner LLC Files Class Action Suit Against AbbVie Inc..NEWS4: Pre-Market Earnings Report for July 27, 2018 :  XOM, CVX, MRK, ABBV, CL, PSX, AON, MCO, TWTR, IMO, WY, SYF.NEWS5: Pre-Market Earnings Report for July 27, 2018 :  XOM, CVX, MRK, ABBV, CL, PSX, AON, MCO, TWTR, IMO, WY, SYF.NEWS6: A guide to biotech’s building boom in South City.NEWS7: Notable ETF Inflow Detected - IUSG, ABBV, CRM, PYPL.NEWS8: Notable ETF Inflow Detected - IUSG, ABBV, CRM, PYPL.NEWS9: AbbVie Q2 Earnings Preview.NEWS10: How The Pieces Add Up: RNDV Headed For $24.NEWS11: How The Pieces Add Up: RNDV Headed For $24.NEWS12: How Gilead Sciences Fared in the Second Quarter.NEWS13: Stryker Reports Revenue Growth of 10.3% in Second Quarter.NEWS14: ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions.

Answer: Decrease